Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3)

Ítems similars

• Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
  per: Gueorguiev, M, et al.
  Publicat: (2010)
• Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
  per: Druce, MR, et al.
  Publicat: (2009)
• Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
  per: Fazio, N, et al.
  Publicat: (2013)
• Effect of Everolimus plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours - Analysis From RADIANT-2
  per: Fazio, N, et al.
  Publicat: (2011)
• The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
  per: Grozinsky-Glasberg, S, et al.
  Publicat: (2009)